Clinical trialObsActive not recruiting
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer - A Norwegian Population Based Observational Study (NORPACT-2)
- Outcome
- Ongoing
- Phase
- Obs
- Status
- Active not recruiting
- Study type
- Observational
- Start
- 1 January 2018
- Expected end
- 31 December 2025
- Enrollment
- 251 participants
- Sites
- 1
- Primary outcomes
- Rate of resectability in both groups (borderline and locally advanced pancreatic cancer)
- Sponsor
- Other
- Results posted
- No
- Last update
- 20 November 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 3
- Registry-listed results paperMolecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced… DOI 10.1080/00365521.2024.2373115↗
- Registry-listed results paperPerformance and safety of diagnostic EUS FNA/FNB and therapeutic ERCP in patients with borderline resectable and locall… DOI 10.1080/00365521.2023.2290456↗
- Registry-listed results paperResection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data f… DOI 10.1093/bjsopen/zrad137↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.